According to the company, opioid analgesics and nonsteroidal anti-inflammatory drugs will continue to hold leading market status in the acute pain space while new analgesics that will launch over the next decade will not have a significant impact on major market sales or the treatment paradigm for acute pain. In 2011, sales of opioid analgesics and nonsteroidal anti-inflammatory drugs combined, made up more than half of the total major market sales, said Andrea Buurma, a Decision Resources analyst. This trend is expected to continue through 2021.
More Articles on Pain Management:
Physician’s Technology Introduces 5th Generation Device for Joint Pain Relief
Sheikh Zayed Institute for Pediatric Surgical Innovation to Open Children’s Pain Medicine Clinic
Interventional Pain Specialist Joins New England Spine Clinic
